Teva launches SYNCareTM to support patients taking Synribo

FRAZER, Pa. — Teva Pharmaceutical on Wednesday announced the launch of SYNCareTM, a program designed to support patients taking Synribo (omacetaxine mepesuccinate) for at-home injection.



Through the program, patients will receive:

• 
  Home delivery of prepared, prescribed doses;


• 
  All supplies needed for home administration;


• 
  Educational and injection training resources; and


• 
  A 24/7 toll-free hotline number.

Synribo recently received approval from the Food and Drug Administration for at-home administration. Adults with chronic or accelerated phase chronic myeloid leukemia who are no longer responding to (or who were not able to tolerate,) two or more tyrosine kinase inhibitors now have the option of administering the drug at home.



"The comprehensive level of support provided through SYNCare will help my patients administer Synribo in their homes," said Meir Wetzler, M.D., FACP, chief of the leukemia section at Roswell Park Cancer Institute. "With supported home administration, patients living with CML are empowered with flexibility in their treatment regimen."



Teva has entered into an exclusive agreement with Diplomat Pharmacy to distribute Synribo to patients at home, the company said. Diplomat will ensure custom preparation by a healthcare professional of each dose and delivery of Synribo directly to the patient's home.